Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Olmetec | Olmesartan medoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | ||
| Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
| Enablex | Darifenacin hydrobromide | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
| Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
| Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | ||
| Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
| Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
| Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | ||
| Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete |
Last Updated : April 28, 2024